| Abstrakt: |
A recent study published in JAMA Pediatrics suggests that adolescents with obesity who are prescribed glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have a 33% lower risk of experiencing suicidal ideation or attempts compared to those who only receive lifestyle intervention. The study, conducted by researchers from the Hebrew University of Jerusalem, analyzed data from over 6900 adolescents with obesity and found no increase in suicidal ideation associated with GLP-1RA use across various subgroups. While the study's observational nature prevents causal inferences, the findings indicate potential avenues for future research on the neuropsychiatric outcomes of GLP-1RAs in adolescents with obesity. [Extracted from the article] |
